Dr Raminderpal Singh2024-06-24T10:00:00
Recently there have been a flurry of announcements from AI-led biotechs around the potential of Large Language Models (LLM) in early drug discovery. In the first of a three-part series, Dr Raminderpal Singh explores what LLMs are, how early stage biotechs can take advantage of them, and what challenges they ...
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-08-20T08:43:00Z
Author Dr Daniel Tillett
2024-01-19T07:40:55
Sponsored by Euretos
2026-07-23T06:20:00
Contributor Laura Lotfi, Drug Target Review
2026-08-20T08:43:00
Author Dr Daniel Tillett
2024-01-24T12:52:38
Sponsored by BellBrook Labs
2026-06-29T06:49:00
Contributor Laura Alvarez, Drug Target Review
2026-05-22T07:38:00
Contributor Dr Helen Bright, Drug Target Review
Site powered by Webvision Cloud